Kawasaki disease

BMJ (Online)

Volumn 338, Issue 7703, 2009, Pages 1133-1138

  Harnden, Anthony ^a   Takahashi, Masato ^b   Burgner, David ^c  

^a UNIVERSITY OF OXFORD   (United Kingdom)

^b UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^c UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; CYCLOPHOSPHAMIDE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; IMMUNOGLOBULIN; METHYLPREDNISOLONE; PENTOXIFYLLINE;

CLINICAL ASSESSMENT; CLINICAL FEATURE; CORONARY ARTERY DISEASE; DIAGNOSTIC ACCURACY; DRUG CONTRAINDICATION; EARLY DIAGNOSIS; FEVER; HIGH RISK POPULATION; HUMAN; INCIDENCE; MUCOCUTANEOUS LYMPH NODE SYNDROME; PLASMAPHERESIS; PRIORITY JOURNAL; REVIEW; SINGLE DRUG DOSE; TREATMENT DURATION;

ADRENAL CORTEX HORMONES; ANTI-INFLAMMATORY AGENTS; ASPIRIN; HUMANS; IMMUNOGLOBULINS, INTRAVENOUS; MUCOCUTANEOUS LYMPH NODE SYNDROME;

EID: 67650075143     PISSN: None     EISSN: 17561833     Source Type: Journal    
DOI: 10.1136/bmj.b1514     Document Type: Review

References (24)

1. Burns JC, Glode MP. Kawasaki syndrome. Lancet 2004;364:533-44.
2. Burgner D, Harnden A. Kawasaki disease: what is the epidemiology telling us about the etiology? Int J Infect Dis 2005;9:185-94.
3. Kushner HI, Bastian JF, Turner CL, Burns JC. The two emergencies of Kawasaki syndrome and the implications for the developing world. Pediatr Infect Dis J 2008;27:377-83.
4. Nakamura Y, Yashiro M, Uehara R, Oki I, Watanabe M, Yanagawa H. Epidemiologic features of Kawasaki disease in Japan: results from the nationwide survey in 2005-2006. J Epidemiol 2008;18:167-72.
5. Harnden A, Alves B, Sheikh A. Rising incidence of Kawasaki disease in England: analysis of hospital admission data. BMJ 2002;324:1424-5.
6. Harnden A, Mayon-White R, Sharma R, Yeates D, Goldacre M, Burgner D. Kawasaki disease in England: ethnicity, urbanisation and respiratory pathogens. Pediatr Infect Dis J 2009;28:21-4.
7. Holman RC, Curns AT, Belay ED, Steiner CA, Effler PV, Yorita KL, et al. Kawasaki syndrome in Hawaii. Pediatr Infect Dis J 2005;24:429-33.
8. Uehara R, Yashiro M, Nakamura Y, Yanagawa H. Kawasaki disease in parents and children. Acta Paediatr 2003;92:694-7.
9. Onouchi Y, Tamari M, Takahashi A, Tsunoda T, Yashiro M, Nakamura Y, et al. A genomewide linkage analysis of Kawasaki disease: evidence for linkage to chromosome 12. J Hum Genet 2007;52:179-90.
10. Burgner D, Davila S, Breunis WB, Ng SB, Li Y, Bonnard C, et al. A genome-wide association study identifies novel and functionally related susceptibility loci for Kawasaki disease. PLoS Genet 2009;5:e1000319.
11. Chang RK. Hospitalizations for Kawasaki disease among children in the United States, 1988-1997. Pediatrics 2002;109:e87.
12. Rowley AH. The etiology of Kawasaki disease: superantigen or conventional antigen? Pediatr Infect Dis J 1999;18:69-70.
13. Newburger JW, Takahashi M, Gerber MA, Gewitz MH, Tani LY, Burns JC, et al. Diagnosis, treatment, and long-term management of Kawasaki disease: a statement for health professionals from the committee on rheumatic fever, endocarditis, and Kawasaki disease, council on cardiovascular disease in the young, American Heart Association. Pediatrics 2004;114:1708-33.
14. Chang FY, Hwang B, Chen SJ, Lee PC, Meng CC, Lu JH. Characteristics of Kawasaki disease in infants younger than six months of age. Pediatr Infect Dis J 2006;25:241-4.
15. Rowley AH. Incomplete (atypical) Kawasaki disease. Pediatr Infect Dis J 2002;21:563-5.
16. Oates-Whitehead RM, Baumer JH, Haines L, Love S, Maconochie IK, Gupta A, et al. Intravenous immunoglobulin for the treatment of Kawasaki disease in children. Cochrane Database Syst Rev 2003;(4):CD004000.
17. Newburger JW, Takahashi M, Beiser AS, Burns JC, Bastian J, Chung KJ, et al. A single intravenous infusion of gamma globulin as compared with four infusions in the treatment of acute Kawasaki syndrome. N Engl J Med 1991;324:1633-9.
18. Baumer JH, Love SJ, Gupta A, Haines LC, Maconochie I, Dua JS. Salicylate for the treatment of Kawasaki disease in children. Cochrane Database Syst Rev 2006;(4):CD004175.
19. Newburger JW, Sleeper LA, McCrindle BW, Minich LL, Gersony W, Vetter VL, et al. Randomized trial of pulsed corticosteroid therapy for primary treatment of Kawasaki disease.N Engl J Med 2007;356:663-75.
20. Miura M, Katada Y, Ishihara J. Time interval of measles vaccination in patients with Kawasaki disease treated with additional intravenous immune globulin. Eur J Pediatr 2004;163:25-9.
21. Kato H, Ichinose E, Kawasaki T. Myocardial infarction in Kawasaki disease: clinical analyses in 195 cases. J Pediatr 1986;108:923-7.
22. Nakamura Y, Aso E, Yashiro M, Uehara R, Watanabe M, Oki I, et al. Mortality amongpersonswith a history of Kawasaki disease in Japan: mortality among males with cardiac sequelae is significantly higher than that of the general population. Circ J 2008;72:134-8.
23. Selamet Tierney ES, Newburger JW. Are patients with Kawasaki disease at risk for premature atherosclerosis? J Pediatr 2007;151:225-8.
24. Kato H, Sugimura T, Akagi T, Sato N, Hashino K, Maeno Y, et al. Long-term consequences of Kawasaki disease. A 10- to 21-year follow-up study of 594 patients. Circulation 1996;94:1379-85.